Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,233 people get MELA articles and Market Currents by email alert.
Get email alerts on MELA »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
Electro-Optical Sciences Seeks Partners for Melanoma Detection DeviceDouglas Cress • Wed, Jun 20, 2007
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
5 Healthcare Companies With Significant Recent Insider Buying (Part IV)Markus Aarnio • Wed, Nov 14, 2012 -
-
-
-
-
-
-
Analyzing Wednesday's Noteworthy Insider Buys And SellsGuruFundPicks • Thu, Dec 22, 2011 -
-
4 Rallying Small-Cap Stocks With Sharp Increases In Shares ShortedKapitall • Fri, Oct 14, 2011
-
-
Buy And Sell Ideas Based On Monday's Top GainersGuruFundPicks • Tue, Sep 27, 2011
-
-
MELA Sciences' CEO Discusses Q2 2012 Results - Earnings Call TranscriptWed, Aug 8, 2012 • 1 Comment
-
GlobeNewswire (Apr 30, 2013)
-
PR Newswire (Apr 23, 2013)
-
GlobeNewswire (Apr 18, 2013)
-
GlobeNewswire (Apr 15, 2013)
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Mar 5, 2013)
-
PR Newswire (Feb 21, 2013)
-
at MarketWatch.com (Feb 12, 2013)
-
GlobeNewswire (Jan 28, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Jan 3, 2013)
-
GlobeNewswire (Nov 9, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Nov 5, 2012)
-
GlobeNewswire (Oct 24, 2012)
MELA vs. ETF Alternatives
Company Description
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 1, 3:46 PM Mela Sciences (MELA -10.6%) takes a hit today after its Q1 revenue misses by a huge margin despite a nearly 12-fold increase over year-ago levels. Revenue for the three months ended March 31 totaled $144,100, up from $11,250 during the same quarter last year but still lagging the analyst consensus by more than 76%, as a sizeable chunk of the quarters revenue from Melafind sales were deferred. 3 Comments [Healthcare, Earnings, On the Move]
- Wednesday, May 1, 4:42 AM MELA Sciences (MELA): Q1 EPS of -$0.17 beats by $0.01. Revenue of $144K misses by $466K. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Wednesday, March 6, 3:18 PM Mela Sciences (MELA -17%) reverses yesterday's post-session gains and sinks on a disappointing Q4. Higher marketing expenses, coupled with an increase in costs associated with installing its Melafinds systems in medical offices, all conspired to pressure margins. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, March 5, 6:47 PM More on Mela Sciences (MELA): Q4 comes in line with estimates. Net loss for quarter was $6.1M, or $0.19 per diluted share, compared to a net loss of $4.5M, or $0.17 per diluted share for Q411. The higher net losses can be attributed to greater SG&A costs, and an increase in direct costs associated with the placement of MelaFind systems in dermatologists' offices. Total revenues were boosted by increased installation of its MelaFind, with 20 additional user agreements signed in Q4. Shares +4.2% AH. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, March 5, 4:29 PM MELA Sciences (MELA): Q4 EPS of -$0.19 in-line. Revenue of $122.3K. Shares -3.4% AH. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
-
- View all 1 replies
-
-
jtimrick
Actually Melafind which is the main product being offered by $MELA was approved on 11-1-11. Here is a link: http://1.usa.gov/WnjnSR - View all 2 replies
-
techwonk: It's a pre-market approval (PMA) see the co. website. Not sure why it still shows as that, they seem to be selling now.
-
techwonk: http://seekingalpha.com/a/o971 Here's a Jan. Editor's pick with more pro and con in the comments.
-
- View all 4 replies
-
techwonk: Well, I'm wrong on this, they got a PMA (preliminary) tho I don't see a final sign off. New article on SA : http://seekingalpha.com/a/rpiv
-
-
- View all 5 replies
-
joe kelly: This is what i get when I have too much cash in my portfolio. Off to 7-11 for smokes and TP to wipe the turd that is MELA away.
-
-
- View all 0 replies
-
Derek Chipman
$MELA - a medical equipment company long sought by hedge funds, will hedge funds buy this speculative $2 play in FY 2013 or steer clear? - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
jrusso9722
There should be an information release, by MELA, in earl April, concluding first quarter, 2012, as well as more frequent news. - View all 0 replies
LATEST REPLIES
-
jtimrick
Actually Melafind which is the main product being offered by $MELA was approved on 11-1-11. Here is a link: http://1.usa.gov/WnjnSR - View all 2 replies
-
techwonk: It's a pre-market approval (PMA) see the co. website. Not sure why it still shows as that, they seem to be selling now.
-
techwonk: http://seekingalpha.com/a/o971 Here's a Jan. Editor's pick with more pro and con in the comments.
-
- View all 4 replies
-
techwonk: Well, I'm wrong on this, they got a PMA (preliminary) tho I don't see a final sign off. New article on SA : http://seekingalpha.com/a/rpiv
-
-
- View all 5 replies
-
joe kelly: This is what i get when I have too much cash in my portfolio. Off to 7-11 for smokes and TP to wipe the turd that is MELA away.
-
-
- View all 1 replies
-
-
- View all 7 replies
-
-
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!
-
- View all 2 replies
-
Ricardo Espinosa: It´s a really strong stock, you won´t beleive how much people in latin america spend on stupid things they think they need. -
-
- View all 2 replies
-
-
-
jrusso9722
Mela Sciences has announced this morning, 11-2-11, that the FDA has approved MelaFind. MELA - View all 1 replies
-
-
- View all 2 replies
-
pat50: This company really needs some market coverage-all the bears who are short rule the chatter.
-
jrusso9722: Hi pat50, Yes, I agree. Saving lives is the issue. Shorters will eat their shorts. MelaFind will save lives---non invasively.